A Phase 2 interventional study of Abemaciclib and Irinotecan in Sarcoma, Ewing and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Active, not recruiting at 29 sites in 7 countries. Open to participants aged 1 Year to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing irinotecan in Sarcoma, Ewing — 4 open to participants now, 6 under way, none of them phase 3. Irinotecan · Sarcoma, Ewing.
Among the 14 studies testing irinotecan in Sarcoma, Ewing, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 10th registered.
250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.
Browse Sarcoma, Ewing studies →4 of the 14 studies testing irinotecan in Sarcoma, Ewing are open now, in 2 countries. Recruiting first, the newest first:
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 1+
Sun Yat-sen University · Sites in China
Ages 18–75
Peking University People's Hospital · Sites in China
Ages 8–40
South Plains Oncology Consortium · Sites in United States
Ages 12 mo–20 yrs
By country, each count listing its studies:
Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.
This study: 1 Year to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 2
First in 2011; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.
Median enrollment 31 across the 14 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Sarcoma, Ewing — fewer than ten, so there is no comparison to draw.
3 of the studies testing irinotecan in Sarcoma, Ewing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02013336South Plains Oncology ConsortiumPhase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | 2026-12 |
| NCT06827717Sun Yat-sen UniversityPhase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma | 2027-04 |
| NCT01864109Memorial Sloan Kettering Cancer CenterIrinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing irinotecan in Sarcoma, Ewing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
disease or confirmed radiological progression or recurrence following first or of treatment of Ewing's sarcoma or Ewing's sarcoma-like tumor
-- Must have one measurable or evaluable lesion per 1.1
Adequate performance status based on age
Adequate hematologic and organ function less than or equal to (≤)14 days prior to Day 1 of Cycle 1:
Must be able to swallow and/or have a gastric/nasogastric tube
-- Participants in the European Union must be able to swallow intact capsules
Exclusion Criteria:
Surgery: Participants who have had, or are planning to have, the following invasive procedures:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the following treatments in a 21-day cycle, continuing until disease progression, unacceptable toxicity, or a criterion for discontinuation was met. * Abemaciclib: 55 mg/m² (milligrams per square meter), administered orally twice daily (BID) for less than (\<18) years or 100 mg administered orally BID for greater than or equal to (≥)18 years. * Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.
Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide
Participants received the following treatments in a 21-day cycle, continuing until disease progression, unacceptable toxicity, or a criterion for discontinuation was met. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.
Drug: Irinotecan · Drug: Temozolomide
Orally
Also known as: LY2835219
IV
Orally
Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian Analysis
PFS was defined as the time from randomization until the first occurrence of documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause in absence of progressive disease, whichever came first. Progressive disease (PD) was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 millimeter (mm), or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.
Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)
PFS Assessed by BIRC by Frequentist Analysis
PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.
Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.36 months)
PFS Assessed by Investigator by Bayesian Analysis
PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.
Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.39 Months)
PFS Assessed by Investigator by Frequentist Analysis
PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.
Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up to 22.39 Months)
Overall Survival (OS)
OS was defined as the time from date of randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
Time frame: From Date of Randomization until Death Due to Any Cause (Up to 26.37 months)
Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) Assessed by BIRC
ORR was defined as the number of participants who achieved the best overall response of complete response (CR) or partial response (PR) as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: From Date of Randomization until Disease Progression, Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.36 Months)
ORR: Percentage of Participants Who Achieved a CR or PR Assessed by Investigator
ORR was defined as the number of participants who achieved the best overall response of CR or PR as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: From Date of Randomization until Disease Progression, Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.39 Months)
Duration of Response (DoR) Assessed by BIRC
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.
Time frame: From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up to 10.7 Months)
DoR Assessed by Investigator
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed, per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.
Time frame: From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up to 12.7 Months)
Percentage of Participants With a Best Overall Response of CR, PR, Stable Disease (SD) or Non-CR/Non-PD: Disease Control Rate (DCR) Assessed by BIRC
Disease control rate (DCR) was the percentage of participants with a best overall response of CR, PR, SD or Non-CR/Non-PD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Non-CR/Non-PD was defined as persistence of one or more non-target lesions and/or maintained tumor marker levels, but without sufficient progression to be considered PD and without complete disappearance to be CR.
Time frame: From Date of Randomization until Disease Progression, or Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.36 Months)
Percentage of Participants With a Best Overall Response of CR, PR or SD: DCR Assessed by Investigator
DCR was the percentage of participants with a best overall response of CR, PR, or SD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease for target lesions, no progression of non-target lesions, and no appearance of new lesions.
Time frame: From Date of Randomization until Disease Progression, or Death Due to Any Cause, Concomitant Radiotherapy/Surgery, or Start of New Anti-Cancer Therapy (Up to 22.39 Months)
Pharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of Abemaciclib
PK: Cmin of Abemaciclib were reported.
Time frame: Pre-dose on Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1; End of irinotecan infusion on Cycle 2 Day 1 and Cycle 4 Day 1
Abemaciclib Product Acceptability
Participants were evaluated for abemaciclib acceptability by asking a question - " Was it easy or difficult for the study participant to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: "Very difficult", "difficult", "neither easy nor difficult", "easy", or "very easy". Acceptability was assessed for formulations: tablets, oral granules, and dispersed tablets.
Time frame: Day 1 of Cycle 1 through Cycle 3 (21-day cycles)
| Milestone | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| Started | 30 | 16 |
| Received at least one dose of study drug | 30 | 15 |
| Completed | 15 | 8 |
| Not completed | 15 | 8 |
| Withdrew: Withdrawal by parent or guardian | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: On study (ongoing) | 14 | 5 |
PFS was defined as the time from randomization until the first occurrence of documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause in absence of progressive disease, whichever came first. Progressive disease (PD) was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 millimeter (mm), or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.
| Months | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| Progression Free Survival (PFS) Assessed by Blinded Independent Review Committee (BIRC) by Bayesian Analysis | NA (NA to NA) | NA (NA to NA) |
PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.
| Months | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| PFS Assessed by BIRC by Frequentist Analysis | 2.79 (1.74 to 13.32) | 2.89 (1.25 to 5.13) |
PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST v1.1 criteria, or date of randomization (whichever was later). Results were obtained using Bayesian analysis and are reported as posterior mean along with its 80% credible interval.
| Months | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| PFS Assessed by Investigator by Bayesian Analysis | NA (NA to NA) | NA (NA to NA) |
PFS was defined as the time from randomization until the first occurrence of documented disease progression per RECIST v1.1 criteria, or death from any cause in absence of progressive disease, whichever came first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. An event was considered when tumor progression or death occurred, with the event date being the earliest date of PD or death. Participants known to be alive and without tumor progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever was later). Results were obtained using frequentist analysis.
| Months | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| PFS Assessed by Investigator by Frequentist Analysis | 2.93 (1.74 to 10.59) | 3.81 (1.41 to 6.94) |
OS was defined as the time from date of randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
| Months | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| Overall Survival (OS) | 21.21 (9.17 to NA) | 6.94 (5.13 to NA) |
ORR was defined as the number of participants who achieved the best overall response of complete response (CR) or partial response (PR) as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| Percentage of Participants | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| Overall Response Rate (ORR): Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) Assessed by BIRC | 10.0 (2.1 to 26.5) | 25.0 (7.3 to 52.4) |
ORR was defined as the number of participants who achieved the best overall response of CR or PR as per RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| Percentage of Participants | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| ORR: Percentage of Participants Who Achieved a CR or PR Assessed by Investigator | 16.7 (5.6 to 34.7) | 18.8 (4.1 to 45.7) |
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.
| Months | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| Duration of Response (DoR) Assessed by BIRC | NA (NA to NA) | NA (NA to NA) |
DoR was defined as the time from the date that measurement criteria for CR or PR (whichever was first recorded) were first met until the first date that recurrent disease or documented disease progression was observed, per RECIST v1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. DoR was calculated for participants with only PR or CR. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants with an observed CR or PR, no confirmed disease progression per RECIST v1.1 criteria, and no death due to any cause were censored at the time of the last adequate post-baseline scan.
| Months | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| DoR Assessed by Investigator | NA (NA to NA) | NA (NA to NA) |
Disease control rate (DCR) was the percentage of participants with a best overall response of CR, PR, SD or Non-CR/Non-PD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Non-CR/Non-PD was defined as persistence of one or more non-target lesions and/or maintained tumor marker levels, but without sufficient progression to be considered PD and without complete disappearance to be CR.
| Percentage of Participants | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| Percentage of Participants With a Best Overall Response of CR, PR, Stable Disease (SD) or Non-CR/Non-PD: Disease Control Rate (DCR) Assessed by BIRC | 60.0 (40.6 to 77.3) | 50.0 (24.7 to 75.4) |
DCR was the percentage of participants with a best overall response of CR, PR, or SD as defined by RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease for target lesions, no progression of non-target lesions, and no appearance of new lesions.
| Percentage of Participants | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| Percentage of Participants With a Best Overall Response of CR, PR or SD: DCR Assessed by Investigator | 60.0 (40.6 to 77.3) | 56.3 (29.9 to 80.3) |
PK: Cmin of Abemaciclib were reported.
| nanogram per milliliter | Abemaciclib + Irinotecan +Temozolomide |
|---|---|
| Pharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of Abemaciclib | 118 ± 95 |
Participants were evaluated for abemaciclib acceptability by asking a question - " Was it easy or difficult for the study participant to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: "Very difficult", "difficult", "neither easy nor difficult", "easy", or "very easy". Acceptability was assessed for formulations: tablets, oral granules, and dispersed tablets.
| Participants | Abemaciclib (Cycle 1 Day 1) | Abemaciclib (Cycle 2 Day 1) | Abemaciclib (Cycle 3 Day 1) |
|---|---|---|---|
| Participant Who Received Abemaciclib Tablet: Participant Responses — Very easy to swallow | 15 | 16 | 11 |
| Participant Who Received Abemaciclib Tablet: Participant Responses — Easy to swallow | 4 | 1 | 2 |
| Participant Who Received Abemaciclib Tablet: Participant Responses — Neither easy nor difficult to swallow | 2 | 1 | 0 |
| Participant Who Received Abemaciclib Tablet: Participant Responses — Difficult to swallow | 1 | 0 | 0 |
| Participant Who Received Abemaciclib Tablet: Participant Responses — Very difficult to swallow | 0 | 0 | 0 |
| Participant Who Received Abemaciclib Tablet: Caregiver Responses — Very easy to swallow | 5 | 7 | 4 |
| Participant Who Received Abemaciclib Tablet: Caregiver Responses — Easy to swallow | 1 | 0 | 1 |
| Participant Who Received Abemaciclib Tablet: Caregiver Responses — Neither easy nor difficult to swallow | 0 | 0 | 0 |
| Participant Who Received Abemaciclib Tablet: Caregiver Responses — Difficult to swallow | 0 | 0 | 0 |
| Participant Who Received Abemaciclib Tablet: Caregiver Responses — Very difficult to swallow | 0 | 0 | 0 |
| Participant Who Received Abemaciclib Oral Granules: Participant Responses — Very easy to swallow | 1 | — | — |
| Participant Who Received Abemaciclib Oral Granules: Participant Responses — Easy to swallow | 0 | — | — |
| Participant Who Received Abemaciclib Oral Granules: Participant Responses — Neither easy nor difficult to swallow | 0 | — | — |
| Participant Who Received Abemaciclib Oral Granules: Participant Responses — Difficult to swallow | 0 | — | — |
| Participant Who Received Abemaciclib Oral Granules: Participant Responses — Very difficult to swallow | 0 | — | — |
| Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Very easy to swallow | — | 1 | — |
| Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Easy to swallow | — | 0 | — |
| Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Neither easy nor difficult to swallow | — | 0 | — |
| Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Difficult to swallow | — | 0 | — |
| Participant Who Received Abemaciclib Oral Granules: Caregiver Responses — Very difficult to swallow | — | 0 | — |
| Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Very easy to swallow | — | — | — |
| Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Easy to swallow | — | — | — |
| Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Neither easy nor difficult to swallow | — | — | — |
| Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Difficult to swallow | — | — | — |
| Participant Who Received Abemaciclib Tablet Dispersed: Participant Responses — Very difficult to swallow | — | — | — |
| Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Very easy to swallow | 0 | 1 | 1 |
| Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Easy to swallow | 1 | 0 | 0 |
| Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Neither easy nor difficult to swallow | 0 | 0 | 0 |
| Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Difficult to swallow | 0 | 0 | 0 |
| Participant Who Received Abemaciclib Tablet Dispersed: Caregiver Responses — Very difficult to swallow | 0 | 0 | 0 |
Collected over Baseline up to end of follow-up (up to 26.37 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib + Irinotecan +Temozolomide | 15/30 (50%) | 12/30 (40%) | 30/30 (100%) |
| Irinotecan +Temozolomide | 8/16 (50%) | 5/15 (33.3%) | 15/15 (100%) |
| Event | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| PyrexiaGeneral disorders | 2/30 | 2/15 |
| Abdominal painGastrointestinal disorders | 3/30 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 3/30 | 0/15 |
| Abdominal pain upperGastrointestinal disorders | 0/30 | 1/15 |
| Catheter site infectionInfections and infestations | 0/30 | 1/15 |
| Clostridial infectionInfections and infestations | 0/30 | 1/15 |
| Bone painMusculoskeletal and connective tissue disorders | 0/30 | 1/15 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/30 | 1/15 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/30 | 0/15 |
| EnterocolitisGastrointestinal disorders | 1/30 | 0/15 |
| Event | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 28/30 | 13/15 |
| AnaemiaBlood and lymphatic system disorders | 19/30 | 6/15 |
| Abdominal painGastrointestinal disorders | 17/30 | 8/15 |
| NauseaGastrointestinal disorders | 17/30 | 7/15 |
| VomitingGastrointestinal disorders | 16/30 | 5/15 |
| Platelet count decreasedInvestigations | 14/30 | 2/15 |
| PyrexiaGeneral disorders | 11/30 | 4/15 |
| Neutrophil count decreasedInvestigations | 10/30 | 2/15 |
| HypokalaemiaMetabolism and nutrition disorders | 10/30 | 1/15 |
| Intermenstrual bleedingReproductive system and breast disorders | 0/9 | 1/3 |
All randomized participants.
| Age, Continuous(Years) | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide | Total |
|---|---|---|---|
| Mean | 16.7 ± 6.7 | 17.1 ± 6.8 | 16.8 ± 6.6 |
| Sex: Female, Male(Participants) | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide | Total |
|---|---|---|---|
| Female | 9 | 4 | 13 |
| Male | 21 | 12 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 8 |
| Not Hispanic or Latino | 20 | 10 | 30 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Race (NIH/OMB)(Participants) | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 18 | 11 | 29 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Region of Enrollment(Participants) | Abemaciclib + Irinotecan +Temozolomide | Irinotecan +Temozolomide | Total |
|---|---|---|---|
| United States | 3 | 2 | 5 |
| Japan | 7 | 2 | 9 |
| Italy | 5 | 0 | 5 |
| France | 4 | 3 | 7 |
| Australia | 1 | 0 | 1 |
| Germany | 1 | 2 | 3 |
| Spain | 9 | 7 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2022 to primary completion in Jan 2025, 27 months.
Results were first posted in Mar 2026, 1 year 1 month after primary completion.
Of 39 phase 2 interventional studies under Sarcoma, Ewing, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 92. This study's 27 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Irinotecan · Temozolomide